Gastric Cancer Market Outlook

Thelansis’s “Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gastric Cancer Overview

Gastric cancer is the fifth most commonly diagnosed cancer worldwide and the fifth leading cause of cancer-related death, with a notably higher prevalence in men. Its pathogenesis is complex and heavily influenced by environmental and infectious risk factors; while Helicobacter pylori infection is the primary driver of distal (non-cardia) gastric cancers, other contributors include high-salt diets, N-nitroso compound exposure, smoked foods, and smoking. Conversely, increased BMI, gastroesophageal reflux disease (GERD), and smoking are strongly associated with the rising incidence of adenocarcinomas of the proximal stomach and gastroesophageal junction (GEJ). Molecularly, fibroblast growth factors (FGFs) play a pivotal role by binding to their receptors (FGFRs), triggering downstream oncogenic signaling cascades. Specifically, the FGFR2b isoform is an emerging prognostic and predictive biomarker. FGFR2b protein overexpression occurs to some degree in up to 38% of advanced gastric cancers—with clinically actionable, high-level overexpression present in approximately 16% of cases—particularly in diffuse-type and scirrhous subtypes. FGFR2 gene amplification, which can occur independently of protein overexpression, is seen in about 5–10% of cases. Both alterations correlate with deeper invasion, infiltrative growth, and a poor prognosis, underscoring the critical importance of emerging targeted treatments like the FGFR2b-directed monoclonal antibody bemarituzumab.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)